AUSTIN, Texas, Feb. 24, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has submitted an application to the U.S. Food and Drug Administration (FDA) for 510(k) ...
Luminex Corporation LMNX recently submitted an application to the FDA, seeking a 510(k) clearance of the VERIGENE II Respiratory Flex Assay. It is the second VERIGENE II assay to be submitted to the ...
Viral panel is designed to test for eight pathogens in up to 96 patients. FDA granted 510(k) approval to Luminex’ xTAG Respiratory Viral Panel FAST (RVP FAST) test for respiratory infections. Designed ...
Luminex Corporation LMNX recently submitted an Emergency Use Authorization application (EUA) to the FDA for the company's new multi-analyte respiratory panel pairing Flu A/B and respiratory syncytial ...
Dr. Stephen will cover the process of developing and manufacturing reliable Luminex biomarker assays, as well as using those assays to test samples. She will examine the development of Ampersand ...
Luminex’s xMAP technology is a microsphere-based multiplexing system. Multiplex assays provide attractive time and labor advantages over singleplex ELISA-based assays. In the Luminex assays, a ...
SAN CARLOS, Calif., April 1, 2015 -- Curiox Biosystems, a leader in miniaturized multiplex technology, announces two successful research collaborations with the Agency for Science, Technology and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback